eprintid: 10206194
rev_number: 6
eprint_status: archive
userid: 699
dir: disk0/10/20/61/94
datestamp: 2025-03-19 09:50:29
lastmod: 2025-03-19 09:50:29
status_changed: 2025-03-19 09:50:29
type: article
metadata_visibility: show
sword_depositor: 699
creators_name: Yates, Tom A
creators_name: Grint, Daniel J
title: Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes
ispublished: inpress
divisions: UCL
divisions: B02
divisions: C10
divisions: D15
note: Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).
date: 2025-03-15
date_type: published
publisher: Elsevier BV
official_url: https://doi.org/10.1016/j.lanmic.2025.101117
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 2370935
doi: 10.1016/j.lanmic.2025.101117
lyricists_name: Yates, Tom
lyricists_id: TYATE82
actors_name: Yates, Tom
actors_id: TYATE82
actors_role: owner
full_text_status: public
publication: The Lancet Microbe
article_number: 101117
issn: 2666-5247
citation:        Yates, Tom A;    Grint, Daniel J;      (2025)    Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes.                   The Lancet Microbe      , Article 101117.  10.1016/j.lanmic.2025.101117 <https://doi.org/10.1016/j.lanmic.2025.101117>.    (In press).    Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10206194/1/Yates%20and%20Grint%20-%20microbiological%20outcomes%20in%20TB%20trials.pdf